Abcam, ab257235, Human GRN (Granulin) knockout HEK-293T cell lysate

Size: 1Kit
GRN KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon2 and 2 bp deletion in exon2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon2 and 2 bp deletion in exon2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-GRN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Granulin also known as progranulin or GRN is a protein with a molecular mass of approximately 68 kDa. This protein is encoded by the GRN gene and is involved in various cellular processes. Granulin is expressed widely within the body particularly in epithelial cells immune cells and neurons. Researchers have developed methods like GRN ELISA and progranulin ELISA to quantitatively measure the levels of granulin in biological samples aiding in further understanding of its role in health and disease.
Biological function summary
Granulin functions as a growth factor involved in tissue repair cell proliferation and inflammation. It does not function as part of a larger protein complex but acts individually in exerting its effects on cells. Granulin influences various aspects of cellular architecture and signaling pathways making it important for maintaining cellular homeostasis. Additionally the granulin protein participates in regulating networks that involve cytokines and growth factors impacting both the innate and adaptive immune responses.
Pathways
Granulin plays significant roles in the MAPK and NF-kB signaling pathways. These pathways critically manage cellular reactions to stress inflammation and other external stimuli. Granulin modulates these processes often interacting with proteins like TNF receptors and interleukins to affect the downstream signaling events. Interactions between granulin and other signaling molecules allow it to integrate into broader networks that oversee various biological responses.
Significant links exist between granulin mutations and frontotemporal dementia (FTD) and Alzheimer's disease. Mutations in the GRN gene often lead to reduced granulin levels contributing to neurodegenerative conditions. These mutations affect the protein's normal function promoting pathological mechanisms associated with neuronal deterioration. Granulin interacts with proteins such as TDP-43 in neurodegenerative diseases where alterations might result in protein aggregation and neurotoxicity. Understanding these connections can lead to potential therapeutic interventions targeting granulin-related pathways.